Pharmamarketeer

Bayer’s Vitrakvi receives first tumor-agnostic approval in EU

Bayer announced that the European Commission has granted marketing authorization in the European Union (EU) for the precision oncology treatment Vitrakvi (larotrectinib). The drug is indicated for the treatment

Medhc-fases-banner
Advertentie(s)